Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;10 Suppl 2(0 2):S93-5.
doi: 10.3816/CLML.2010.s.017.

Immune modulators as therapeutic agents for cutaneous T-cell lymphoma

Alain H Rook  1 , Bernice Benoit, Ellen J Kim, Carmela C Vittorio, Aleksandra Anshelevich, Brian A Raphael, Camille E Introcaso, Jennifer M Gardner, Katherine G Evans, Kelly Morrissey, Sara Samimi, Amy C Musiek, Louise C Showe, Mariusz A Wasik, Maria Wysocka
Affiliations

Immune modulators as therapeutic agents for cutaneous T-cell lymphoma

Alain H Rook et al. Clin Lymphoma Myeloma Leuk. 2010 Sep.

Abstract

Cutaneous T-cell lymphoma at all stages appears to be responsive to immune modulatory therapeutic approaches. We describe here the mechanistic rationale for the use of interferons, interleukin-12, retinoids, Toll-like receptor agonists, photopheresis and combinations of immune preserving, immune stimulatory therapies for CTCL.

PubMed Disclaimer

Conflict of interest statement

There were no conflicts of interest in regard to this publication

References

    1. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798–812. - PMC - PubMed
    1. Walsh PT, Benoit BM, Wysocka M, Dalton NM, Turka LA, Rook AH. A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. J Invest Dermatol. 2006;126(3):690–2. - PubMed
    1. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):311–21. - PubMed
    1. Lai L, Hui CK, Leung N, Lau GK. Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine. 2006;1(3):255–62. - PMC - PubMed
    1. McGinnis KS, Ubriani R, Newton S, Junkins-Hopkins JM, Vittorio CC, Kim EJ, et al. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sezary syndrome. Arch Dermatol. 2005;141(9):1176–8. - PubMed

MeSH terms

Substances